GHIT Fund Announces New Drug, Vaccine, Diagnostic Investments, Appoints New Director

Global Health Innovative Technology Fund: GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria, and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis
“The Global Health Innovative Technology (GHIT) Fund announced today a total of 2.86 billion yen (US$25.8 million) to support 10 partnerships to develop new lifesaving drugs, vaccines, and diagnostics for malaria, tuberculosis, dengue, leishmaniasis, and schistosomiasis. This includes three new projects and seven that will receive continued funding…” (3/28).

Global Health Innovative Technology Fund: GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director
“The Global Health Innovative Technology Fund (GHIT) today announced the appointment of Catherine Ohura as the organization’s new CEO and executive director. Ohura brings depth and breadth of expertise and invaluable experience working for R&D and commercial functions…” (3/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.